Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers

Seminars in Oncology

Volumn 29, Issue 1, 2002, Pages 27-36

  Herbst, Roy S ^a,b   Langer, Corey J ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; MONOCLONAL ANTIBODY; PACLITAXEL;

ALLERGIC REACTION; ANAPHYLAXIS; ANGIOGENESIS; APOPTOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; TUMOR NECROSIS;

EID: 0036124415     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31525     Document Type: Article

References (57)

1. Epidermal growth factor-related peptides and their receptors in human malignancies
2. Epidermal growth factor
3. Growth factor receptor tyrosine kinases
4. Receptors for epidermal growth factor and other polypeptide mitogens
5. Epidermal growth factor
6. The type I (EGFR-related) family of growth factor receptors and their ligands
7. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: A mechanism for receptor transregulation
8. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
9. The EGF receptor: Structure, regulation and potential role in malignancy
10. The epidermal growth factor receptor as a multi-functional allosteric protein
11. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
12. Tumour angiogenesis
13. Epidermal growth factor EGF increases the in vitro invasion, motility and adhesion interactions of the primary renal cell carcinoma cell line, A704
14. Effects of EGF, bFGF, NGF and PDGF(bb) on cell proliferative, migratory and invasive capacities of human brain-tumor biopsies in vitro
15. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth
16. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals
17. Anti-tumor and cell cycle responses-in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin
18. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
19. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
20. The biological effects of anti-epidermal growth factor receptor and ionizing radiation in human head and neck tumor cell lines
21. The EGF receptor system as a target for antitumor therapy
22. Modulation of pro-epidermal growth factor, pro-transforming growth factor α and epidermal growth factor receptor gene expression in human renal carcinomas
23. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer
24. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells
25. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
26. Phase II trial of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
27. Dose-schedule-finding, pharmacokinetic (PK), biologic, and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor
28. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck
29. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (IRESSA) inhibits HER2/neu (erb-2) overexpressing breast tumor cells
30. Phase I and imaging trial of indium-111 labeled anti-EGF receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma
31. Monoclonal antibodies against EGFR VIII are tumor specific and react with breast and lung carcinomas and malignant gliomas
32. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines
33. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma
34. Phase I trial and tumour localization of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
35. Potent anti-tumor activity of ABX-EGF, a fully human monoclonal antibody to epidermal growth factor receptor
36. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
37. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
38. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
39. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
40. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
41. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
42. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
43. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5
44. 1 arrest in prostatic cancer cell line DU145
45. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
46. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
47. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
48. The epidermal growth factor receptor (EGFR) - A new target in cancer therapy
49. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer
50. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
51. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors
52. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
53. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
54. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy
55. Evaluation of HER2/neu expression in lung tumors by immunohistochemistry and fluorescence in situ hybridization (FISH)
56. C225 anti-EGFR antibody potentiates radiation (RT) and chemotherapy (CT) cytotoxicity in human non-small cell lung cancer (NSCLC) cells in vitro and in vivo
57. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)